S232: EFFICACY AND TOXICITY OF CAR-T CELLS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS, A NEW REFERENCE: THE FRENCH EXPERIENCE OF THE NATIONAL LOC NETWORK

Podobne zapisy

• Preliminary evidence of CAR T‐cell therapy activity in vitreoretinal lymphomas: An LOC network study
  od: Cécile Pivert, i wsp.
  Wydane: (2025-08-01)
• S232: EFFICACY AND TOXICITY OF CAR-T CELLS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS, A NEW REFERENCE: THE FRENCH EXPERIENCE OF THE NATIONAL LOC NETWORK
  od: Sylvain Choquet, i wsp.
  Wydane: (2023-08-01)
• Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
  od: Marion Alcantara, i wsp.
  Wydane: (2024-09-01)
• Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
  od: Marion Alcantara, i wsp.
  Wydane: (2024-10-01)
• Cytoflavin in Polychemotherapy of Breast Cancer
  od: V. A. Kashuro, i wsp.
  Wydane: (2020-05-01)